Immix Biopharma, Inc.
IMMX Nasdaq
SEC CIK 1873835
Follow Immix Biopharma
Weekly email: filings, results
Net income
−$13.9M
−83.6% vs same quarter last year
EPS, diluted
−$0.19
+20.8% vs same quarter last year
Operating cash flow
−$12.3M
−108.4% vs same quarter last year
Operating income
−$15.9M
−108.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$29.4M |
| FY24 | −$21.6M |
| FY23 | −$15.4M |
| FY22 | −$8.2M |
| FY21 | −$24.4M |
| FY20 | −$1.1M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$24.7M |
| FY24 | −$15.8M |
| FY23 | −$11.4M |
| FY22 | - |
| FY21 | −$1.6M |
| FY20 | - |
| FY19 | - |